103 related articles for article (PubMed ID: 11859427)
1. Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors.
Buvoli M; Langer SJ; Bialik S; Leinwand LA
Gene Ther; 2002 Feb; 9(3):227-31. PubMed ID: 11859427
[TBL] [Abstract][Full Text] [Related]
2. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo.
Steinwaerder DS; Lieber A
Gene Ther; 2000 Apr; 7(7):556-67. PubMed ID: 10819570
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated skeletal muscle transcriptional targeting using chimeric tissue-specific promoters.
Frauli M; Ribault S; Neuville P; Augé F; Calenda V
Med Sci Monit; 2003 Feb; 9(2):BR78-84. PubMed ID: 12601283
[TBL] [Abstract][Full Text] [Related]
4. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
5. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements.
de Leeuw B; Su M; ter Horst M; Iwata S; Rodijk M; Hoeben RC; Messing A; Smitt PS; Brenner M
J Neurosci Res; 2006 Apr; 83(5):744-53. PubMed ID: 16496373
[TBL] [Abstract][Full Text] [Related]
6. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.
Kügler S; Kilic E; Bähr M
Gene Ther; 2003 Feb; 10(4):337-47. PubMed ID: 12595892
[TBL] [Abstract][Full Text] [Related]
7. Insulation of a conditionally expressed transgene in an adenoviral vector.
Vassaux G; Hurst HC; Lemoine NR
Gene Ther; 1999 Jun; 6(6):1192-7. PubMed ID: 10455425
[TBL] [Abstract][Full Text] [Related]
8. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
9. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.
Rubinchik S; Lowe S; Jia Z; Norris J; Dong J
Gene Ther; 2001 Feb; 8(3):247-53. PubMed ID: 11313797
[TBL] [Abstract][Full Text] [Related]
10. Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.
Hoffmann D; Jogler C; Wildner O
J Gene Med; 2005 Oct; 7(10):1356-66. PubMed ID: 15945123
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
12. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
13. Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression.
Perlman H; Liu H; Georganas C; Woods JM; Amin MA; Koch AE; Wickham T; Kovesdi I; Mano T; Walsh K; Pope RM
J Rheumatol; 2002 Aug; 29(8):1593-600. PubMed ID: 12180715
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
15. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
[TBL] [Abstract][Full Text] [Related]
16. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.
Hurtado Picó A; Wang X; Sipo I; Siemetzki U; Eberle J; Poller W; Fechner H
Mol Ther; 2005 Apr; 11(4):563-77. PubMed ID: 15771959
[TBL] [Abstract][Full Text] [Related]
17. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
18. B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element.
Werner M; Kraunus J; Baum C; Brocker T
Gene Ther; 2004 Jun; 11(12):992-1000. PubMed ID: 15029232
[TBL] [Abstract][Full Text] [Related]
19. Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression.
Millecamps S; Kiefer H; Navarro V; Geoffroy MC; Robert JJ; Finiels F; Mallet J; Barkats M
Nat Biotechnol; 1999 Sep; 17(9):865-9. PubMed ID: 10471926
[TBL] [Abstract][Full Text] [Related]
20. Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies.
Sasaki S; Smith JM; Takase K; Okuda K; Ishii N; Takeshita F
Int J Mol Med; 2006 Aug; 18(2):289-97. PubMed ID: 16820937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
